Novo Nordisk has announced breakthrough results from its PIONEER TEENS trial, proving that oral semaglutide for type 2 diabetes in children offers superior glycemic control and a well-tolerated safety profile for adolescents.
Eli Lilly’s latest Phase 3 study, ACHIEVE-4, demonstrates that the oral GLP-1 Foundayo (orforglipron) provides significant cardiovascular protection, weight loss, and glycemic control for adults with type 2 diabetes.
Amgen has announced successful topline results from its Phase 3 trial evaluating a subcutaneous formulation of TEPEZZA® for Thyroid Eye Disease, offering a new, convenient delivery method.
Johnson & Johnson has announced breakthrough one-year data for ICOTYDE (icotrokinra), demonstrating that the once-daily oral peptide maintains high rates of skin clearance and a favorable safety profile in patients with plaque psoriasis.
Novo Nordisk and United Biotechnology announce that their jointly developed UBT251 triple agonist targeting GLP-1, GIP, and glucagon receptors outperformed semaglutide 1 mg in a 24-week Chinese phase 2 trial, setting the stage for global phase 3 development.
Novartis unveils over 20 abstracts at AAD 2026, highlighting Rhapsido’s (remibrutinib) early intervention in CSU and Cosentyx’s (secukinumab) sustained performance in complex skin diseases.
Eli Lilly and Company announced positive topline results from TRANSCEND-T2D-1, a landmark Phase 3 clinical trial evaluating retatrutide, an investigational triple hormone receptor agonist. The trial results demonstrate [Read More…]
ohnson & Johnson has announced FDA approval of ICOTYDE (icotrokinra), the first and only IL-23R targeted oral peptide designed for first-line systemic treatment of moderate-to-severe plaque psoriasis. This groundbreaking approval represents a paradigm shift in dermatology, offering patients unprecedented efficacy with complete skin clearance in over 70% of clinical trial participants.
Groundbreaking clinical trial demonstrates that FreeStyle Libre continuous glucose monitoring technology significantly improves glucose management in people with Type 2 diabetes using basal insulin therapy, with patients achieving better HbA1c reduction and more time spent in healthy glucose ranges compared to traditional fingerstick monitoring.
In the Phase 3 AFFIRM study, SKYRIZI (risankizumab) achieved superiority in co-primary endpoints of clinical remission and endoscopic response at week 12 for subcutaneous induction in patients with Crohn’s disease.
